ArticleCardiovascular diabetology2026
Triglyceride-glucose index and mortality in critically ill patients with cardiovascular-kidney-metabolic syndrome stage 4.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The triglyceride-glucose (TyG) index is a well-established surrogate marker of insulin resistance (IR). Previous studies have linked higher TyG levels to an increased risk of cardiovascular events in individuals with early-stage (0-3) Cardiovascular-Kidney-Metabolic Syndrome (CKM). However, its prognostic value in critically ill patients with CKM stage 4 remains unclear. In this retrospective study, we analyzed clinical data from critically ill CKM stage 4 patients in the MIMIC-IV database. The TyG index was calculated and patients were categorized into tertiles. Cox proportional hazards models and restricted cubic spline (RCS) analyses were used to evaluate the association between the TyG index and all-cause mortality. A total of 3,125 patients were included, of whom 65.22% were male.= The 1-year all-cause mortality was 34.18% overall (28.79% in Q1, 35.06% in Q2, and 38.68% in Q3; P < 0.05). In multivariable Cox regression, each 1-standard deviation increase in the TyG index was associated with a 23% higher risk of 1-year mortality (HR = 1.23, 95% CI 1.09-1.39). Compared with the Q1 group, patients in Q3 had a 30% higher 1-year mortality risk (HR = 1.30, 95% CI 1.08-1.55). RCS analysis showed a linear positive relationship between the TyG index and mortality (P for non-linearity > 0.05). These findings indicate that higher TyG levels are independently associated with increased short- and long-term mortality in critically ill patients with CKM stage 4. The TyG index may provide a simple indicator of acute metabolic disturbances and could support early risk stratification in this population. However, its role in clinical decision-making and potential utility in guiding interventions require confirmation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.